Pre-existing neutralizing antibody provides the first line of defence against pathogens in general. For influenza virus, annual vaccinations are given to maintain protective levels of antibody against the currently circulating strains. Here we report that after booster vaccination there was a rapid and robust influenzaspecific IgG 1 antibody-secreting plasma cell (ASC) response that peaked at approximately day 7 and accounted for up to 6% of peripheral blood B cells. These ASCs could be distinguished from influenza-specific IgG 1 memory B cells that peaked 14-21 days after vaccination and averaged 1% of all B cells. Importantly, as much as 80% of ASCs purified at the peak of the response were influenza specific. This ASC response was characterized by a highly restricted B-cell receptor (BCR) repertoire that in some donors was dominated by only a few B-cell clones. This pauciclonal response, however, showed extensive intraclonal diversification from accumulated somatic mutations. We used the immunoglobulin variable regions isolated from sorted single ASCs to produce over 50 human monoclonal antibodies (mAbs) that bound to the three influenza vaccine strains with high affinity. This strategy demonstrates that we can generate multiple highaffinity mAbs from humans within a month after vaccination. The panel of influenza-virus-specific human mAbs allowed us to address the issue of original antigenic sin (OAS): the phenomenon where the induced antibody shows higher affinity to a previously encountered influenza virus strain compared with the virus strain present in the vaccine 1 . However, we found that most of the influenza-virus-specific mAbs showed the highest affinity for the current vaccine strain. Thus, OAS does not seem to be a common occurrence in normal, healthy adults receiving influenza vaccination.
Influenza causes 36,000 deaths annually in the USA alone, and the influenza pandemic of 1918 caused an estimated 50 million deaths worldwide 2 . Outbreaks of avian influenza infections in human populations that caused substantially higher mortality rates foresee the possibility of another deadly pandemic 3 . The challenge of influenza has long been to design vaccines that induce long-lasting immunity against a pathogen that rapidly alters its appearance to the immune system by mutating (antigenic drift) and exchanging (antigenic shift) its components. Antibodies play a key role in protection against influenza infection [4] [5] [6] [7] . However, the underlying B-cell response leading to the rapid production of ASCs that secrete antibodies is only beginning to be understood [8] [9] [10] [11] [12] . Critically, we do not yet know if B-cell memory can provide sufficient protection early in the response to counteract variant strains of influenza or if the response is dominated by antibodies previously generated against divergent viruses in an OAS fashion. Finally, of profound clinical significance is the possibility that the early ASC response observed after immunization can be exploited to generate therapeutic or diagnostic mAbs rapidly to emerging influenza virus strains, or to any immunizing antigen.
To determine the dynamics and magnitude of the human antiinfluenza response, we analysed the frequency of ASCs and memory B cells in a time course after vaccination. The ASC response was quite transient, peaking at approximately day 7 and returning to barely detectable levels by day 14 after vaccination ( Fig. 1a, b) . The frequency of influenza-specific ASCs averaged 6.4% (about 2,500 ASCs per millilitre of blood) at day 7, and accounted for up to 16% of all B cells (range for ten donors: 1.1-16%, Fig. 1b) . Also, most of these ASCs were generated during the vaccination response as almost all ASCs expressed the protein bound by the K i-67 antibody, indicating recent proliferation, and most expressed homogenously high levels of human leukocyte antigen DR (HLA-DR) 13 ( Fig. 1c) . Importantly, analysis of IgG-secreting ASCs isolated by cell sorting at day 7 post-immunization demonstrated that most were influenzavaccine-specific (ranging from 20% to 85%, average 70%; Fig. 1d ). The ASCs were mainly IgG positive, with minor components of IgAand IgM-positive cells (data not shown), suggesting an origin from the memory B-cell compartment. The memory B-cell response was also quantified 14 . Increasing from low levels before vaccination, influenza-specific memory B cells peaked a week after the ASC response at 14-28 days after vaccination and averaged 8.2% of the IgG 1 memory B cells, or about 1% of all B cells (Fig. 1e) . We conclude that influenza vaccination results in a massive burst of IgG 1 ASCs that are predominantly influenza reactive and peak at approximately day 7 post-immunization.
The rapid accumulation of ASCs suggests that the response could be highly clonal in nature, limiting the early influenza response. Some clonal activation of ASCs occurs after tetanus vaccination 12 . We therefore analysed the immunoglobulin repertoire breadth (that is, the variable genes and junctional diversity) of the influenza-specific ASCs. Influenza vaccination caused a surprisingly pauci-clonal response, with some donors being dominated by the progeny of only a few expanded B-cell clones ( Fig. 2a and Supplementary Fig. 1a ).
Clonal expansions accounted for 43% of the ASC variable regions from the 14 immunized donors, including three with over 70% clonality (Fig. 2a) . In stark contrast, based on VH regions sequenced from our laboratory in a comparable fashion [15] [16] [17] , naive and memory B cells (IgM or IgG) isolated from blood were rarely or never clonal, whereas for tonsillar B cells only 10% of IgM and 12% of IgG germinal centre and memory cells were clonally related.
Immunoglobulin variable gene somatic hypermutation allows for the generation of high-affinity antibodies 18, 19 . Surprisingly, the influenza-specific ASCs had accumulated more somatic mutations than any normal population of B cells. Considering the various donors (Fig. 2b) , the ASCs averaged 19.4 6 3.5 VH gene mutations, which is greater than that of germinal centre or memory B cells which average 13.6 6 4.8 mutations for IgG or 8.4 6 3.8 mutations for IgM. A surprising 11% (41/405) of the ASC VH gene segments have more than 30 of 300 (or about 10%) of the total nucleotides altered (Fig. 2c) . A preference for complementarity-determining region replacement mutations suggests that the ASCs were functionally selected (Supplementary Table 1 ). These observations suggest the origin of the anti-influenza ASCs is predominantly memory B cells that probably accumulated new mutations on this and on previous rounds of activation.
It is not known how often the ASCs that are induced by vaccination produce high-affinity antibodies against influenza. Immunoglobulin variable region genes from ASCs can be used to express specific antibodies 20 . We therefore used the variable gene transcripts of isolated single ASCs to express recombinant mAbs in the human 293 cell line ( Supplementary Fig. 1b and Methods). The ASCs of five donors were isolated at day 7 post-vaccination. From these, 71% (61/86) of the antibodies bound with high affinity to either native antigens of Influenza-and total IgG-specific ELISPOT assays from several donors gave similar results. e, Percentage of influenza-specific memory cells per total IgG-positive memory cells after mitogen stimulation as measured by ELISPOT at 0, 7, 14, 28 and 80 days post-vaccination as previously described 14 .
the influenza vaccine strains (53/86, 61%) or to components of the vaccine only (8/86, 9%) (Fig. 3 , Table 1 and Supplementary Fig. 2 ). We suspect that the epitopes found only in the vaccine are exposed on the fixed virions or are from added preservatives. In comparison, none of the 86 mAbs generated from naive B cells 15 ( Fig. 3b ) and only one of 54 antibodies from random IgG memory B cells bound to the influenza vaccine strains with appreciable affinity (data not shown). The antibodies produced from the influenza-specific ASCs bound to any of the three vaccine components with similar frequency (Table 1 and Supplementary Fig. 2 ). Analysis of viral antigen specificity by immunoprecipitation and western blot ( Supplementary Fig.  3 ) found that 60% of the influenza-reactive antibodies bound to haemagglutinin, of which half were haemagglutination inhibiting (HAI) (Fig. 3c and Table 1 ). Twelve per cent of the antibodies bound to neuraminidase or to other minor components of the vaccine likely residual to the purification of haemagglutinin and neuraminidase during vaccine production. Ten per cent of the antibodies did not precipitate native antigens and bound only to epitopes on denatured viral proteins detectable by western blot. Importantly, each of three representative HAI 1 antibodies against influenza-A (anti-H3N2) and one against influenza-B from the day-7 ASCs (Table 1, Supplementary Fig. 4 ). In conclusion, after influenza vaccination, early ASCs produce functional antibodies that bind with high affinity and likely provide early protection. Although most of the ASCs arise only after vaccination (Fig. la) , 29% of the antibodies generated did not detectably bind to the Fig. 1b) bind to a mixture of the three influenza vaccine strain virions with high affinity. In total, 71% of the ASC antibodies bound either native antigens of influenza viruses freshly grown in eggs (53/86, 62%), or to antigens within the vaccine only (8/86, 9% , not shown). Antibodies from each of the five donors were influenza specific (by donor, 34, 13, 11, 15 and 21 antibodies were generated, of which 45-85% were influenza specific). Individual antibody strain specificities are shown in Table 1 and Supplementary Fig. 2 . b, None of 86 naive B-cell antibodies bound influenza. c, Analysis by immunoprecipitation and western blot ( Supplementary Fig. 3 ) identified the specific viral antigens bound. Haemagglutination assays identified those antibodies that were inhibiting ( LETTERS influenza strains or whole vaccine (Fig. 3c) . Possible causes include errors introduced by the reverse-transcription polymerase chain reaction (RT-PCR) steps (though PCR errors were rare, Supplementary Table 2) , targeting of non-viral or denatured components of the vaccine or antigens only evident physiologically, bystander activation of non-specific memory cells 8 , or displacement of non-specific plasma cells from the bone marrow 13 . The last possibility is unlikely as expression of HLA-DR 13 and K i-67 (Fig. 1c) by the ASCs suggests they were newly generated.
The long-held theory of OAS suggests that new influenza variants will evade surveillance when memory B cells reactive to previous viral strains dominate the response 1 (Fig. 4a, b) . In the 2006/7 season, antibodies were analysed from five donors who had also been vaccinated in the 2005/6 season and one in 1991, so that reactive memory cells should have been readily available for an OAS response. Importantly, each of the 19 anti-B strain antibodies bound to the new B strain with equal, and in most cases with greater, affinity than the previous vaccine strains (Fig. 4c and Supplementary Fig. 2 ). This adaptation occurred despite the 10% or less difference of the Thus we conclude that even for the earliest detectable influenzaspecific B cells after vaccination, the ASCs, OAS does not limit reactivity to newly introduced influenza strains.
In conclusion, we show that after influenza vaccination we can isolate an almost entirely antigen-specific population of ASCs that comprise about 5% of all blood-borne B cells. Further, our findings help to resolve a major, long-standing obstacle in the field of medicine 21 : the rapid production of fully human mAbs. Antibody or serum therapy has been demonstrated to treat a plethora of diseases effectively, but it is not widely used because sometimes fatal anaphylactic responses and serum sickness are common. These obstacles can only be overcome by using fully human mAbs. Our findings demonstrate that we can now generate human mAbs from the antigen-specific ASCs directly, and within only weeks of vaccination ( Supplementary Fig. 1c) . With a modern resurgence of interest in monoclonal antibody therapy, we anticipate that antibodies produced from post-vaccination ASCs will generate substantial advances for the treatment of infectious diseases. Conventional wisdom holds that the level of pre-formed antibody is the main correlate of protection against influenza virus. However, our results, showing the rapidity of the antibody response after vaccination and the high affinity of the antibodies produced, strongly suggest that the recall response could also play a role in protective immunity. This antibody would not, of course, prevent initial infection but could play a crucial role in preventing the spread of virus and bringing about faster resolution of the infection. This notion is supported by our finding that OAS was not a significant aspect of the memory response, as the antibodies produced were highly specific to the immunizing antigen. Enumeration of IgG or influenza-specific B cells has been previously described, including: ELISPOT 22 and polyclonal activation of memory B cells 14, 22 . HAI titres and viral neutralization were determined by standard procedures 23 .
METHODS SUMMARY
Monoclonal antibodies were tested for HAI at 30 mg ml 21 and five twofold serial dilutions. The ASCs were identified as CD3 
/CD19
1 /CD27 hi /CD38 hi cells. Isolation of other B-cell types and methods for RT-PCR of the variable genes were as previously described 15, 17 . An average of 35 variable gene sequences was analysed from each donor (Methods and Supplementary Information). The leader and constant regions that are rarely targeted by somatic mutation were primed for RT and PCR to avoid biases between populations for the variable gene repertoire and clonality determinations. The single-cell RT-PCR methods and the procedures for production of recombinant mAbs were as previously described 15, 24 . Monoclonal antibodies were screened against fresh influenza virions grown in chicken eggs. Antibody affinities (K d ) were calculated by nonlinear regression (GraphPad Prism software) of influenza enzyme-linked immunosorbent assay (ELISA) curves plotted from eight dilutions of antibody ranging from 10 mg ml 21 to 0.125 mg ml 21 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
